However, once IL-6 was knocked out, the tumor cell migration was greatly reduced even lower than the control group, which suggested that the increased cell migration may be associated with the cell signaling pathways by these therapies, and the effect of sorafenib was significantly greater than IFN-α, which may be associated with the up-regulation of p-MEK and p-ERK for sorafenib treatment and the up-regulation of p-JAK2/p-STAT3 for IFN-α, respectively. Here, STAT3 is linked to neoplasm.